Pelham

Researchers are evaluating the safety and effectiveness of a new medicine called CagriSema in helping adults living with obesity, with or without type 2 diabetes, to lose weight. This phase 3 clinical study compares two different weekly doses of CagriSema against an existing medicine, semaglutide. The study aims to understand how well these treatments support weight loss over a long period. Participants in this study will be randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given by weekly injection under the skin for 72 weeks. The study lasts about 83 weeks, covering treatment and follow-up periods to observe effects and safety. During the study, participants will have regular assessments to monitor body weight, body mass index BMI, waist size, cholesterol levels, blood sugar control HbA1c, and quality of life. Researchers will track changes from the start of treatment to the end of 72 weeks, including weight loss milestones and health measurements. Safety will also be closely monitored through reports of any adverse events until the study ends.

This research aims to assess the effectiveness, safety, and tolerability of switching from glucagon-like peptide-1 receptor agonists GLP-1RA to maridebart cafraglutide in adults with obesity or overweight. The study focuses on adults with a body mass index of 25 or higher who have lost at least 10% of their body weight using weekly GLP-1RA treatment and have stable weight and gastrointestinal tolerability. Participants will be randomly assigned to one of two groups, each receiving a different dosing schedule of maridebart cafraglutide administered by subcutaneous injection during the treatment period. This is a phase 3, open-label trial with a parallel study model designed to evaluate the treatment effects over a period culminating at week 68. Throughout the study, participants will undergo assessments including body weight changes, plasma concentration of maridebart cafraglutide, and monitoring for treatment-emergent adverse events up to 84 weeks. The primary outcome measured is the percent change in body weight from baseline at week 68. Secondary outcomes include weight maintenance and safety evaluations, with participants expected to follow trial procedures for the entire duration.